Analgesia in Inguinal Hernia Repair Using a Cyclooxygenase-2-specific Inhibitor
Randomised Controlled Trial - Multimodal Analgesia in Inguinal Hernia Repair Using a Cyclooxygenase-2-specific Inhibitor: A Randomised Controlled Trial
1 other identifier
interventional
60
1 country
1
Brief Summary
Acute pain is the result of activating nociceptive pathways in both the peripheral and central nervous system. The origin of most acute pain from surgical stimulation is the mechanical trauma of the local tissue and the subsequent acute inflammatory response. No studies have investigated the combined use of anti-inflammatory analgesics with spinal anaesthesia/analgesia for pre, intra and postoperative multimodal pain protection in patients undergoing day-case IHR. The aim of the investigators study is therefore to assess the efficacy of preoperative combined administration of etoricoxib and standard spinal anaesthesia in the reduction of postoperative pain following IHR.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jan 2015
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2016
CompletedFirst Submitted
Initial submission to the registry
August 17, 2016
CompletedFirst Posted
Study publicly available on registry
August 31, 2016
CompletedAugust 31, 2016
August 1, 2016
Same day
August 17, 2016
August 30, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Pain VAS Score
In the post operative period
Each four hours until 24 hours
Study Arms (2)
Etoricoxib
ACTIVE COMPARATOR120mg of oral Etoricoxib under the brand name Arcoxia® (Merck Sharp \& Dohme) one hour prior to spinal anaesthesia induction
Placebo
PLACEBO COMPARATOR120mg of oral Placebo the same amount as the drug administrated one hour prior to spinal anaesthesia induction
Interventions
120mg of oral etoricoxib under the brand name Arcoxia® (Merck Sharp \& Dohme) one hour prior to spinal anaesthesia induction
Eligibility Criteria
You may qualify if:
- American Society Anesthesiology Class I and II
You may not qualify if:
- Under treatment with Non Steroid Antinflammatory Drug
- Under Opioid treatment
- Peptic ulcer
- Liver insufficiency
- Renal insufficiency
- Asthma
- Cardiovascular disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Bnai Zion Medical Center
Haifa, Israel
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Luis A Gaitini, M.D.
Bnai Zion Medical Center
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- M.D.
Study Record Dates
First Submitted
August 17, 2016
First Posted
August 31, 2016
Study Start
January 1, 2015
Primary Completion
January 1, 2015
Study Completion
January 1, 2016
Last Updated
August 31, 2016
Record last verified: 2016-08
Data Sharing
- IPD Sharing
- Will share